ASCO GU 2023 Prostate Cancer

Viewing 1-20 of 95 articles

ASCO GU 2023: Identifying Prostate Cancer Patient Subgroups Based on Their Preferences for Key Attributes of Androgen Deprivation Therapies

ASCO GU 2023: Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2023: 18F-DCFPyL PET in First Biochemical Recurrence and Initial Staging: Concordance with Conventional Imaging

ASCO GU 2023: Radium-223 for mCRPC, a Real-World Experience Study from 7 Galician Medical Centers

ASCO GU 2023: Patterns of Failure After Radiotherapy in Patients with Prostate Cancer Re-Staged with 18F-DCFPyL PSMA-PET: A Regional Cohort Analysis

ASCO GU 2023: Lutetium-177 PSMA Radioligand Therapy for mCRPC in Germany: Population-Based Data with Multicenter Validation from 2016 to 2020

ASCO GU 2023: Predictive and Prognostic Potential of Pretreatment 68Ga-PSMA PET Tumor Heterogeneity Index in Patients with mCRPC

ASCO GU 2023: Socioeconomic Vulnerability and the Risk of Genitourinary Cancer Mortality Among United States Counties

ASCO GU 2023: Evaluation of ctDNA in Patients Treated with Lutetium-177-PSMA-617

ASCO GU 2023: Ending Cancer as We Know It: Predicting Future Cancer Progress

ASCO GU 2023: Patient Perspective on Fatigue and Its Management for Advanced Prostate Cancer Treated with Androgen Receptor Inhibitors (ARIs)

ASCO GU 2023: Prognostic Biomarkers and Clinical Outcomes in Neuroendocrine Prostate Cancer (NEPC)

ASCO GU 2023: Genomic Alterations in Patients with Prostate Cancer with Liver Metastases

ASCO GU 2023: Early Outcomes from Lutetium Lu-177 Vipivotide Tetraxetan Treatment in Patients Selected for Therapy with Piflufolastat F-18 PET Imaging

ASCO GU 2023: Use of a Navigable Interface for Integrated Whole Genome and Transcriptome Sequencing as a Platform for Pursuit of Therapeutic Targets in Advanced Prostate Cancers

ASCO GU 2023: The Impact of Genomic Biomarkers on a Validated Clinical Risk Prediction Model for Upgrading/upstaging Among Men with Low-Risk Prostate Cancer

ASCO GU 2023: Ability of STAR-CAP Staging System to Prognosticate Risk of Subsequent Therapies After Initial Treatment of M0 Prostate Cancer

ASCO GU 2023: The Impact of F-18 PSMA PET Imaging on Clinical Decision-Making in Prostate Cancer Across Disease States

ASCO GU 2023: Patterns of Failure with 18F-DCFPyL PSMA PET/CT in the Post-Prostatectomy Setting: A Regional Cohort Analysis

ASCO GU 2023: NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

1
2
3
4
5